Skip to main content

Table 3 Outcome of 6 months of oral vitamin D supplementation

From: Clinical and serological association of plasma 25-hydroxyvitamin D (25(OH)D) levels in lupus and the short-term effects of oral vitamin D supplementation

Parameter

High dose (n = 44)

Routine dose (n = 47)

p value

Vitamin D at 6 months

Median (IQR) ng/ml

34.12 (15.4)

34.61 (12.7)

0.16

Change in vitamin D over 6 months

Median (IQR) ng/ml

9.5 (14.5)

2.6 (14.6)

0.04

Vitamin D deficient at baseline (< 20 ng/ml)

13

13

0.88

Vitamin D insufficient at baseline (20.1–29.9 ng/ml)

20

20

Vitamin D sufficient at baseline (≥ 30 ng/ml)

11

14

Vitamin D deficient at 6months (< 20 ng/ml)

6

2

0.021

Vitamin D Insufficient at 6months (21–29 ng/ml)

10

23

Vitamin D sufficient at 6months (≥ 30 ng/ml)

28

22

Vitamin D levels improved

22

20

0.76

Vitamin D levels remained same

18

22

Vitamin D worsened

4

5

Any Flare

8

6

0.37

Major flare

4

1

0.17

Minor flare

4

5

0.51

SLEDAI 2KG 6 months

Median (IQR)

2 (4)

2 (2)

0.76

Δ SLEDAI 2KG median (min, max)

0 (− 4, 9)

0 (–4, 5)

0.81

C3 (mg/dl) median (IQR)

100.3 (35)

104 (32)

0.32

ΔC3 (mg/dl) median (IQR)

– 5.5 (24.9)

+ 2 (52)

0.59

C4 (mg/dl) median (IQR)

17.3 (11)

17.7 (10)

0.98

Δ C4 (mg/dl) median (IQR)

– 2.4 (7.9)

– 0.7 (6.6)

0.59

Low complements (C3/C4)

12

14

0.82

Improved C3/C4

6

4

0.75

Worsened C3/C4

6

7

Anti-dsDNA median (IQR)

14.11 (51)

48.2 (135)

0.08

Δ Anti-dsDNA median (IQR)

– 15.2 (50.02)

– 2.8 (72.4)

0.06

Positive anti-dsDNA

7

16

0.87

Normalised anti-dsDNA (baseline positive- 6 months negative)

19

11

0.14

Worsening anti-dsDNA (negative at baseline and positive at 6 months)

2

4

  1. C3, C4 complement component 3, 4, SLEDAI2K systemic lupus erythematosus disease activity index 2000, SLEDAI 2KG systemic lupus erythematosus disease activity index 2000 with glucocorticoids